PT group slams Spain's dual-pricing for drugs
A group representing parallel trade firms, the European Association of Euro-pharmaceutical Companies (EAEPC), has announced the filing of a complaint to the European Commission against the Spanish government over alleged "dual-pricing practices" by major drug firms. A law introduced in July 2006 provides a framework which, the plaintiff argues, can be exploited by manufacturers to set a different price to wholesalers, based on whether their products are sold in the Spanish market, or exported to other parts of the European Union.
According to a statement issued by the EAEPC: "by encouraging such an anti-competitive practice, the Spanish government infringes its loyalty obligation towards the Community, laid down in the article 10 of the Treaty."
2006 law "fragments" EU Single Market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze